In humans, mutations in MC4R are the most common cause of genetic obesity (2, 4) and the use of setmelanotide, an MC4R agonist, is an effective pharmacotherapy for the treatment of monogenetic and syndromic obesity phenotypes (5, 6). This evidence concerns the gene MC4R and Genetic obesity.